PRLD Stock Analysis: Buy, Sell, or Hold?
PRLD - Prelude Therapeutics Incorporated
$4.91
0.00 (0.00%)
▲
5d:
+19.76%
30d:
+40.29%
90d:
+42.32%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When PRLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: PRLD is 11.8% above its trading range ($4.39). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: PRLD is 11.8% above its trading range ($4.39). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: PRLD is currently trading at $4.91, which is considered slightly high relative to its 30-day fair value range of $3.88 to $4.39. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.2) compared to its historical average (34.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PRLD is in a strong uptrend. The price is approaching resistance at $4.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PRLD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.00 (+62.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PRLD is in a strong uptrend. The price is approaching resistance at $4.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PRLD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.00 (+62.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.88 -
$4.39
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.0%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 62.9% below Wall St target ($8.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to 11.8% overvaluation
Trading Range Analysis
30-Day Trading Range
$3.88 -
$4.39
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.40
Resistance Level
$4.38
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.22
Wall Street Target
$8.00
(+62.9%)
Revenue Growth (YoY)
41.0%
PE vs Historical
-5.2 vs 34.9
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 10:33 PM ET
Data refreshes hourly during market hours. Next update: 11:33 PM
Data refreshes hourly during market hours. Next update: 11:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRLD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David P Bonita
BUY
2815315 shares
2026-04-21
Orbimed Advisors Llc
BUY
2815315 shares
2026-04-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
